



## BÖLÜM 17

### MİDENİN MALİGN TÜMÖRLERİ

Mustafa YENİ<sup>1</sup>

#### 1. GİRİŞ

Mide kanserleri çoğunlukla geç belirti vermesi ve hastalığa özgü semptomlarının olmaması nedeniyle sinsi ilerleyen bir hastalıktır. Mide de görülen tümörlerinin %90-95'i maligndir, bu malign tümörlerin %95'e yakın kısmını adenokarsinom, %4'ünü lenfoma, %1'ini ise malign mezenkimal tümörler oluşturmaktadır (1). Diğer nadir tümörler ise karsinoidler, anjiosarkom, karsinokarsinom ve yassı hücreli karsinomdur. Mideye metastaz hematogen yol ile nadiren örneğin melanoma veya meme gibi diğer bölgelerden olur. Daha sıklıkla komşu organların malign tümörleri direk olarak (örneğin pankreas veya kolon) veya peritoneal implantasyon yoluyla (örneğin over) invaze eder.

#### 2. EPİDEMİYOLOJİ

Mide kanseri tüm dünyada önemli bir sağlık sorunudur. Kanser İstatistikleri 2020 raporuna göre 27.600 yeni mide kanseri vakası görüleceği düşünülmektedir. Ayrıca ABD'de mide kanseri nedeniyle 11.010 kişinin öleceği tahmin edilmektedir. Globocan 2020'ye göre ise mide kanseri, 2020 yılında her iki cinsiyetten yeni

<sup>1</sup> Op. Dr., Sağlık Bilimleri Üniversitesi Erzurum Bölge Eğitim ve Araştırma Hastanesi Genel Cerrahi AD., mustafayeni31@hotmail.com

**Tablo 17.1. Amerikan Ortak Kanser Komitesi'nin (8.baskı) evreleme kılavuzu, mide kanseri klinik evrelemesi.**

Evre	T	N	M
0	T <sub>is</sub>	N <sub>0</sub>	M <sub>0</sub>
I	T <sub>1</sub>	N <sub>0</sub>	M <sub>0</sub>
I	T <sub>2</sub>	N <sub>0</sub>	M <sub>0</sub>
IIA	T <sub>1</sub>	N <sub>1</sub> , N <sub>2</sub> veya N <sub>3</sub>	M <sub>0</sub>
IIA	T <sub>2</sub>	N <sub>1</sub> , N <sub>2</sub> veya N <sub>3</sub>	M <sub>0</sub>
IIB	T <sub>3</sub>	N <sub>0</sub>	M <sub>0</sub>
IIB	T <sub>4a</sub>	N <sub>0</sub>	M <sub>0</sub>
III	T <sub>3</sub>	N <sub>1</sub> , N <sub>2</sub> veya N <sub>3</sub>	M <sub>0</sub>
III	T <sub>4a</sub>	N <sub>1</sub> , N <sub>2</sub> veya N <sub>3</sub>	M <sub>0</sub>
IVA	T <sub>4b</sub>	Herhangi N	M <sub>0</sub>
IVB	Herhangi T	Herhangi N	M <sub>1</sub>

## KAYNAKLAR

- Küçükzeybek Y, Akyol M, Bayoğlu İV, et al. Midede Adenokarsinom ve Nöroendokrin Karsinom Birlikteliği, Bir Olgu Sunumu ve Literatürün Gözden Geçirilmesi. *Van Tıp Dergisi*. 2015;22(2):114-117.
- Kalaycı T, İliklerden UH. Emergency gastric cancer: Are there any differences between indications, morbidity, and mortality? *International Medicine*. 2021;3(2):50-58.
- NASİROV DM, AKYÜREK DN. MİDE KANSERİNDE R0 REZEKSİYON YAPILAN HASTALARDA uPA, uPAR VE PAİ-1'İN PROGNOZ VE SAĞKALIM ÜZERİNE ETKİSİNİN ARAŞTIRILMASI.
- Çevik BA, Pirinççi E. Beslenme ve Kanser. *Firat Tıp Dergisi*. 2017;22(1).
- Clark GW, Smyrk TC, Burdiles P, et al. Is Barrett's metaplasia the source of adenocarcinomas of the cardia? *Archives of surgery*. 1994;129(6):609-614.
- Chan AOO, Wong B, Feldman M, et al. Risk factors for gastric cancer. *UpToDate*. 2005;9:7.
- Taylor R, Piper D. The carcinogenic effect of cigarette smoke: The effect of cigarette smoke on human gastric mucosal cells in organ culture. *Cancer*. 1977;39(6):2520-2523.
- Edgren G, Hjalgrim H, Rostgaard K, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. *American journal of epidemiology*. 2010;172(11):1280-1285.
- Correa P, Houghton. *Carcinogenesis of Helicobacter pylori Gastroenterology*. 2007;133(2):659-672.
- Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. *Gastroenterology*. 2006;130(1):188-206.
- McCull KE, Watabe H, Derakhshan MH. Role of gastric atrophy in mediating negative association between Helicobacter pylori infection and reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma. *Gut*. 2008;57(6):721-723.
- Iizasa H, Nanbo A, Nishikawa J, et al. Epstein-Barr Virus (EBV)-associated gastric carcinoma. *Viruses*. 2012;4(12):3420-3439.

13. Zur Hausen A, Van Rees B, Van Beek J, et al. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. *Journal of clinical pathology*. 2004;57(5):487-491.
14. Norton JA, Ham CM, Jacques Van Dam R, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. *Annals of surgery*. 2007;245(6):873.
15. Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. *Gastroenterology*. 2012;143(1):35-47. e32.
16. Kalayci T, Ilıklar UH. The Role of Latent Transforming Growth Factor  $\beta$  Binding Protein 2 (LTBP2) in the Diagnosis and Stage Discrimination of Gastric Cancer. *Indian Journal of Surgery*. 2021:1-6.
17. Wanebo HJ, Kennedy B, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. *Annals of surgery*. 1993;218(5):583.
18. ÇOŞKUN S. Çok kesitli bilgisayarlı tomografide insidental olarak saptanan mide duvar kalınlığı artışının gastroskopi bulguları ile karşılaştırılması/The comparison of increased gastric wall thickness found incidentally by the multislice computed tomography with gastroscopy findings. 2011.
19. Botet J, Lightdale C, Zauber A, et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. *Radiology*. 1991;181(2):426-432.
20. Feig BW, Berger DH, Fuhrman GM. The MD Anderson surgical oncology handbook: Lippincott Williams & Wilkins; 2006.
21. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. *Gastroenterology*. 2012;143(3):550-563.
22. Zhang C, Yamada N, Wu Y-L, et al. Helicobacter pylori infection, glandular atrophy and intestinal metaplasia in superficial gastritis, gastric erosion, erosive gastritis, gastric ulcer and early gastric cancer. *World Journal of Gastroenterology: WJG*. 2005;11(6):791.
23. Gologan A, Graham DY, Sepulveda AR. Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. *Clinics in laboratory medicine*. 2005;25(1):197-222.
24. Filipe MI, Muñoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. *International journal of cancer*. 1994;57(3):324-329.
25. You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. *International journal of cancer*. 1999;83(5):615-619.
26. Varis K, Ihamäki T, Härkönen M, et al. Gastric morphology, function, and immunology in first-degree relatives of probands with pernicious anemia and controls. *Scandinavian journal of gastroenterology*. 1979;14(2):129-139.
27. Stengel JZ, Jones DP. Endoscopic Cancer Screening and Surveillance. *GI/Liver Secrets Plus E-Book*. 2010:446.
28. Yoon WJ, Lee DH, Jung YJ, et al. Histologic characteristics of gastric polyps in Korea: emphasis on discrepancy between endoscopic forceps biopsy and endoscopic mucosal resection specimen. *World Journal of Gastroenterology: WJG*. 2006;12(25):4029.
29. Endoscopy ASfG. The role of endoscopy in the surveillance of premalignant conditions of the upper gastrointestinal tract. *Gastrointest Endosc*. 1998;48(6):633-638.
30. Shimoyama S, Aoki F, Kawahara M, et al. CASE REPORT: Early Gastric Cancer Development in a Familial Adenomatous Polyposis Patient. *Digestive diseases and sciences*. 2004;49(2):260.
31. Orłowska J, Jarosz D, Pachlewski J, et al. Malignant transformation of benign epithelial gastric polyps. *American Journal of Gastroenterology (Springer Nature)*. 1995;90(12).
32. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. *The American journal of surgical pathology*. 2000;24(2):167-176.
33. Koh J, Wang T. Tumours in stomach. *Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 7th ed Philadelphia, Saunders*. 2002;1:829-845.

34. Hansson L-E, Nyrén O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. *New England Journal of Medicine*. 1996;335(4):242-249.
35. Neubauer A, Thiede C, Alpen B, et al. Cure of *Helicobacter pylori* infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. *Journal of the National Cancer Institute*. 1997;89(18):1350-1355.
36. Axon A, Forman D. *Helicobacter gastroduodenitis*: a serious infectious disease. Antibiotic treatment may prevent deaths in the decades ahead. British Medical Journal Publishing Group; 1997.
37. Eslick GD, Lim LL-Y, Byles JE, et al. Association of *Helicobacter pylori* infection with gastric carcinoma: a meta-analysis. *The American journal of gastroenterology*. 1999;94(9):2373-2379.
38. Müller A. Multistep activation of the *Helicobacter pylori* effector CagA. *The Journal of clinical investigation*. 2012;122(4):1192-1195.
39. Levine PH, Stemmermann G, Lennette ET, et al. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma. *International journal of cancer*. 1995;60(5):642-644.
40. Nakamura S, Ueki T, Yao T, et al. Epstein-Barr virus in gastric carcinoma with lymphoid stroma. Special reference to its detection by the polymerase chain reaction and in situ hybridization in 99 tumors, including a morphologic analysis. *Cancer*. 1994;73(9):2239-2249.
41. Caygill C, Hill M, Kirkham J, et al. Mortality from cancer following gastric cancer surgery for benign conditions. *Lancet*. 1986;2:929-931.
42. Schaefer N, Sinning C, Standop J, et al. Treatment and prognosis of gastric stump carcinoma in comparison with primary proximal gastric cancer. *The American journal of surgery*. 2007;194(1):63-67.
43. Ono H. Early gastric cancer: diagnosis, pathology, treatment techniques and treatment outcomes. *European journal of gastroenterology & hepatology*. 2006;18(8):863-866.
44. Siewert J, Fink U, Sendler A, et al. Gastric cancer. *Current problems in surgery*. 1997;34(11):835-939.
45. Xi H, Zhang K, Wei B, et al. Significance and contemplation of clinical diagnosis and therapy on the renewal of the eighth edition of gastric cancer TNM staging system. *Zhonghua wei chang wai ke za zhi= Chinese journal of gastrointestinal surgery*. 2017;20(2):166-170.
46. CC ESBDC. AJCC cancer staging manual. New York, NY: Springer; 2010.